Global siRNA Drugs Market Growth (Status and Outlook) 2024-2030

Global siRNA Drugs Market Growth (Status and Outlook) 2024-2030

According to this study, the global siRNA Drugs market size will reach US$ million by 2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report presents a comprehensive overview, market shares, and growth opportunities of siRNA Drugs market by product type, application, key players and key regions and countries.

Segmentation by product type:
Without GalNAc-conjugated
With GalNAc-conjugated

Segmentation by Application:
Genetic Disease
Cancers
Other

This report also splits the market by region:
United States
China
Europe
Other regions:
Japan
South Korea
Southeast Asia
Rest of world

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:
Alnylam
Novartis
Sirnaomics
Ribo Life Science

Please note: The report will take approximately 2 business days to prepare and deliver.